Capricorn Fund Managers Ltd has initiated a new stake in Axogen (AXGN), acquiring 687,600 shares valued at approximately $22.36 million in Q1 2026, according to an SEC filing. This investment now represents 3.55% of Capricorn’s U.S. equity assets, highlighting a significant commitment to a company that specializes in surgical solutions for peripheral nerve repair.
Axogen’s stock has surged 139.5% over the past year, significantly outperforming the S&P 500, and is poised for further growth following the FDA’s approval of its Avance product. Despite a history of GAAP losses, Axogen reported an adjusted profit in 2025, and management anticipates at least an 18% revenue increase in 2026, bolstered by improved reimbursement prospects. This strategic move by Capricorn suggests confidence in Axogen’s recovery trajectory and market potential.
Investors should watch for Axogen’s upcoming earnings report on April 28, which could provide critical insights into its financial health and validate Capricorn’s bullish stance.
Source: fool.com